Pembrolizumab as Neoadjuvant Treatment in HCC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03337841|
Recruitment Status : Unknown
Verified November 2017 by Masatoshi Kudo, Kindai University.
Recruitment status was: Not yet recruiting
First Posted : November 9, 2017
Last Update Posted : November 9, 2017
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Masatoshi Kudo, Kindai University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||October 31, 2019|
|Estimated Study Completion Date :||October 31, 2020|